Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice

Journal of Vascular Surgery
Abbey SchepersPaul H A Quax

Abstract

The aim of this study was to assess whether the anti-inflammatory agent dexamethasone can inhibit vein graft thickening without the occurrence of serious side effects. Venous interposition grafting was performed in the common carotid artery of hypercholesterolemic ApoE3Leiden transgenic mice. Mice were treated with dexamethasone (0.15 mg.kg(-1).d(-1) orally), and after 28 days, vein graft thickening was quantified. Treatment with dexamethasone resulted in a significant 43% reduction in lesion area without changes in lesion composition when compared with nontreated controls. However, dexamethasone, when administered for a prolonged period of time, is known for its potentially serious side effects. To overcome these potential side effects of prolonged dexamethasone treatment, the effect of a short-term 7-day dexamethasone treatment was studied. This short dexamethasone treatment resulted in a 49% decrease of vein graft thickening at 28 days. Furthermore, it was demonstrated that dexamethasone treatment led to reduced local expression of several proinflammatory cytokines and factors in the vein grafts 24 hours after surgery. Finally, observations in mice were verified in human saphenous organ cultures. Exposure to dexamethasone fo...Continue Reading

References

May 1, 1986·The American Journal of Medicine·D J Nashel
Jun 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·K AsaiF Kuzuya
Jan 14, 1999·The New England Journal of Medicine·R Ross
Jun 11, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·R J AielloP M Milos
Jun 22, 1999·The New England Journal of Medicine·G D Sloop
Nov 24, 1999·Atherosclerosis·T J Reape, P H Groot
Jul 18, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Michael A ZimmermanAlden H Harken
Sep 17, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·J H P LardenoyeP H A Quax
Dec 12, 2002·Journal of the American College of Cardiology·Francesco VersaciUNKNOWN Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation Study
Oct 1, 2003·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Xiaoshun LiuIvan De Scheerder
May 19, 2004·European Journal of Clinical Investigation·G PasterkampD P V De Kleijn
Jul 13, 2004·The American Journal of Cardiology·Rainer HoffmannPeter Hanrath

❮ Previous
Next ❯

Citations

Aug 8, 2008·Pacing and Clinical Electrophysiology : PACE·Guilherme FenelonAngelo A V DE Paola
Jun 25, 2014·Environmental Technology·Saleh SulaimanaRafik Karaman
May 31, 2013·Perfusion·M Zakkar, R Kanagasabay
Dec 3, 2008·Journal of Biomechanical Engineering·Mohammed S El-KurdiDavid A Vorp
Feb 26, 2009·British Journal of Pharmacology·Patrick W F HadokeBrian R Walker
Jul 19, 2019·Frontiers in Immunology·Jessica Hoppstädter, Alaina J Ammit
Feb 9, 2018·Frontiers in Cardiovascular Medicine·Margreet R de Vries, Paul H A Quax
Mar 30, 2018·Frontiers in Cardiovascular Medicine·Matthijs Steven Ruiter, Maurizio Pesce
Jun 17, 2020·Journal of Cardiovascular Translational Research·Fabiana BaganhaMargreet R de Vries
May 20, 2016·Nature Reviews. Cardiology·Margreet R de VriesPaul H A Quax
Jan 23, 2020·Molecular and Cellular Endocrinology·Ronald J van der Sluis, Menno Hoekstra

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.